Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

被引：0
|
作者：
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
机构：
[1] Univ Calif Los Angeles Med Ctr, Santa Monica, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[5] Vanadro LLC, Urbandale, IA USA
[6] Univ Southern Calif, Los Angeles, CA USA
[7] Translat Res Oncol US, Los Angeles, CA USA
[8] TORL Biotherapeut, Culver City, CA USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3082
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors.
    Shapiro, Geoffrey
    LoRusso, Patricia
    Vaishampayan, Ulka N.
    Kittaneh, Muaiad
    Hilton, John Frederick
    Cleary, James M.
    Velastegui, Karen
    Xuan, Dawei
    Hua, Steven
    Shazer, Ronald L.
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
    Jang, Sekwon
    Powderly, John D.
    Spira, Alexander I.
    Bakkacha, Ouiam
    Loo, Deryk
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
    Subbiah, V.
    Falchook, G.
    Davis, A. A.
    Wang, J. S.
    de Miguel, M.
    Santoro, A.
    Maur, M.
    Aljumaily, R.
    Boni, V.
    de Speville, B. Doger
    Sun, Y.
    Du, Y.
    Lakshmikanthan, S.
    Bedse, G.
    Ward, A.
    Zweidler-McKay, P.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S73
  • [26] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
    Zhao, H.
    Ma, Y.
    Meng, X.
    Wu, L.
    Fan, Y.
    Zheng, Y.
    Liu, Z.
    Ji, Y.
    Lv, D.
    Luo, S.
    Sommerhalder, D.
    Fu, S.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhao, Y.
    Wang, Y.
    Chin, S.
    Xue, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
  • [27] A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
    Lee, Keun Wook
    Oh, Do-Youn
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Kim, Na Hyung
    Woo, Ahmi
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).
    Boni, Valentina
    Rixe, Oliver
    Rasco, Drew
    Gomez-Roca, Carlos
    Calvo, Emiliano
    Morris, John C.
    Tolcher, Anthony W.
    Assadourian, Sylvie
    Guillemin, Helene
    Delord, Jean-Pierre
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [29] ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.
    Ghazaly, Essam Ahmed
    Joel, Simon
    Gribben, John G.
    Mohammad, Tariq
    Emiloju, Oluwadunni
    Stavraka, Chara
    Hopkins, Tom
    Gabra, Hani
    Wasan, Harpreet
    Habib, Nagy A.
    Leonard, Robert C. F.
    McGuigan, Christopher
    Slusarczyk, Magdalena
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
    Yk, Wang
    Gong, Jifang
    Sun, Yuping
    Zhang, Jian
    Ni, Shuqin
    Hou, Jie
    Chen, Xiaohua
    Wang, Yusheng
    Yu, Qin
    Qu, Xiangdong
    Du, Yejie
    Wei, Li
    Yu, Tao
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 382 - 382
12345